Value of [
Atypical carcinoid
Bronchial carcinoid
Neuroendocrine tumour
PET
Pulmonary carcinoid
Somatostatin receptor
Typical carcinoid
[18F]FDG
[68Ga]Ga-DOTATATE
[68Ga]Ga-DOTATOC
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
07 May 2022
07 May 2022
Historique:
received:
26
01
2022
accepted:
25
04
2022
entrez:
7
5
2022
pubmed:
8
5
2022
medline:
8
5
2022
Statut:
epublish
Résumé
Although most guidelines suggest performing a positron emission tomography/computed tomography (PET/CT) with somatostatin receptor (SSTR) ligands for staging of pulmonary carcinoid tumours (PC), only a limited number of studies have evaluated the role of this imaging tool in this specific patient population. The preoperative differentiation between typical carcinoid (TC) and atypical carcinoid (AC) and the extent of dissemination (N/M status) are crucial factors for treatment allocation and prognosis of these patients. Therefore, we performed a pathology-based retrospective analysis of the value of SSTR PET/CT in tumour grading and detection of nodal and metastatic involvement of PC and compared this with the previous literature and with [ SSTR PET/CT scans performed between January 2007 and May 2020 in the context of PC were included. If available, [ A total of 86 SSTR PET/CT scans performed in 86 patients with PC were retrospectively analysed. [ Our findings confirm the higher SSTR ligand uptake in TC compared to AC and vice versa for [
Sections du résumé
BACKGROUND
BACKGROUND
Although most guidelines suggest performing a positron emission tomography/computed tomography (PET/CT) with somatostatin receptor (SSTR) ligands for staging of pulmonary carcinoid tumours (PC), only a limited number of studies have evaluated the role of this imaging tool in this specific patient population. The preoperative differentiation between typical carcinoid (TC) and atypical carcinoid (AC) and the extent of dissemination (N/M status) are crucial factors for treatment allocation and prognosis of these patients. Therefore, we performed a pathology-based retrospective analysis of the value of SSTR PET/CT in tumour grading and detection of nodal and metastatic involvement of PC and compared this with the previous literature and with [
METHODS
METHODS
SSTR PET/CT scans performed between January 2007 and May 2020 in the context of PC were included. If available, [
RESULTS
RESULTS
A total of 86 SSTR PET/CT scans performed in 86 patients with PC were retrospectively analysed. [
CONCLUSION
CONCLUSIONS
Our findings confirm the higher SSTR ligand uptake in TC compared to AC and vice versa for [
Identifiants
pubmed: 35524900
doi: 10.1186/s13550-022-00900-3
pii: 10.1186/s13550-022-00900-3
pmc: PMC9079198
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28Informations de copyright
© 2022. The Author(s).
Références
Ann Nucl Med. 2009 Oct;23(8):745-51
pubmed: 19784877
Semin Nucl Med. 1995 Jul;25(3):251-61
pubmed: 7570044
Virchows Arch. 2001 Dec;439(6):787-97
pubmed: 11787852
Ann Oncol. 2015 Aug;26(8):1604-20
pubmed: 25646366
Eur J Cardiothorac Surg. 2006 Nov;30(5):787-92
pubmed: 16971134
J Thorac Oncol. 2020 Oct;15(10):1577-1598
pubmed: 32663527
Tumour Biol. 2014 Sep;35(9):8369-77
pubmed: 24850179
Eur J Cardiothorac Surg. 2015 Sep;48(3):441-7; discussion 447
pubmed: 25564217
Eur Radiol. 2016 Mar;26(3):900-9
pubmed: 26162577
J Nucl Med. 2017 May;58(5):756-761
pubmed: 28082438
Eur J Radiol. 2015 Oct;84(10):1866-72
pubmed: 26152870
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Ann Thorac Surg. 2013 Oct;96(4):1156-1162
pubmed: 23915584
Nucl Med Commun. 2009 Apr;30(4):281-6
pubmed: 19247211
Medicine (Baltimore). 2019 Mar;98(10):e14769
pubmed: 30855482
Nucl Med Commun. 2020 Oct;41(10):1040-1046
pubmed: 32732596
Discov Med. 2012 Jul;14(74):71-81
pubmed: 22846204
Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3033-3046
pubmed: 32617641
Ann Oncol. 2021 Apr;32(4):439-451
pubmed: 33482246
Eur J Cardiothorac Surg. 2007 Feb;31(2):186-91
pubmed: 17140801
J Thorac Oncol. 2009 May;4(5):568-77
pubmed: 19357537
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
Eur J Cardiothorac Surg. 2007 Feb;31(2):192-7
pubmed: 17196822
Curr Opin Endocrinol Diabetes Obes. 2020 Jun;27(3):146-154
pubmed: 32250975
Radiographics. 2013 Oct;33(6):1631-49
pubmed: 24108555
EJNMMI Res. 2015 Dec;5(1):53
pubmed: 26458908
J Nucl Med. 1990 Sep;31(9):1501-9
pubmed: 1975618
Ann Oncol. 2012 Oct;23 Suppl 7:vii120-3
pubmed: 22997444
J Nucl Med. 2021 Sep 1;62(9):1278-1284
pubmed: 33579809
Eur J Nucl Med Mol Imaging. 2014 May;41(5):856-64
pubmed: 24435773
QJM. 1998 Apr;91(4):295-301
pubmed: 9666953
Eur J Cardiothorac Surg. 2014 Apr;45(4):677-86
pubmed: 24099733
Interact Cardiovasc Thorac Surg. 2019 Jun 1;28(6):957-960
pubmed: 30753507
Ann Thorac Surg. 2018 Jan;105(1):207-213
pubmed: 29132704
Thorax. 2015 Apr;70(4):379-81
pubmed: 25124060
Clin Lung Cancer. 2021 May;22(3):161-169
pubmed: 33618994
Best Pract Res Clin Endocrinol Metab. 2021 Jan;35(1):101513
pubmed: 34045044
Lung. 2017 Dec;195(6):789-798
pubmed: 29022070
Cancer Imaging. 2011 Jun 15;11:70-5
pubmed: 21697027
J Nucl Med. 2016 Dec;57(12):1949-1956
pubmed: 27811124
Future Oncol. 2018 Jan;14(2):111-122
pubmed: 29072093
Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):311-331
pubmed: 30510849
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
J Nucl Med. 2009 Dec;50(12):1927-32
pubmed: 19910422
J Nucl Med. 2009 Aug;50(8):1214-21
pubmed: 19617343
Nucl Med Commun. 2019 May;40(5):517-524
pubmed: 30694875
Cancer. 2008 Nov 15;113(10):2655-64
pubmed: 18853416
Ann Oncol. 2010 Mar;21(3):548-555
pubmed: 19759190
Clin Nucl Med. 2015 Mar;40(3):e183-9
pubmed: 25608152
Cancer. 2008 Jun;112(11):2447-55
pubmed: 18383518